Version May 2024
Ophthalmic infections/conditions: Ophthalmic:
Drops:Instill 1 to 2 drops in affected eye(s) 3 to 4 times daily; to obtain rapid relief in acute conditions, instill 1 to 2 drops every 1 to 2 hours (generally for the first 2 to 3 days).
Ointment: Apply 2 to 3 applications in affected eye(s) daily; for continued effect if drops are used during the day, apply at bedtime.
There are no dosage adjustments provided in the manufacturer’s labeling.
There are no dosage adjustments provided in the manufacturer’s labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.
Cardiovascular (with high doses): Cardiac arrhythmia, increased blood pressure, palpitations, tachycardia
Central nervous system (with high doses): Central nervous system depression, dizziness, drowsiness, headache, insomnia, nervousness
Gastrointestinal: Dry mucous membranes
Miscellaneous: Burn
Ophthalmic: Blurred vision
Respiratory: Rhinorrhea, sneezing, stinging sensation of the nose
Known hypersensitivity to framycetin, other aminoglycosides antibiotics, or any component of the formulation
Because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity may exist with other Streptomyces-derived antibiotics (eg, neomycin, paromomycin, kanamycin)
Concerns related to adverse effects:
• Superinfection: Prolonged use may result in fungal or bacterial superinfection.
Special populations:
• Contact lens wearers: Formulation contains benzalkonium chloride, which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.
Not available in the US
Yes
Ophthalmic: Wash hands prior to administration. For topical ophthalmic use only. Avoid touching tip of applicator to eye or other surfaces.
Note: Not approved in the United States.
Ophthalmic infection/conditions: Treatment of ophthalmic infections caused by susceptible bacteria (eg, Staphylococcus aureus, Proteus spp., Pseudomonas aeruginosa, coliforms); treatment of blepharitis, conjunctivitis, corneal ulcers, abrasions, burns, and styes; prophylaxis following removal of foreign bodies.
None known.
There are no known significant interactions.
Improvement of infection/symptoms
Broad spectrum aminoglycoside antibiotic that is usually bactericidal; appears to inhibit protein synthesis in susceptible bacteria by binding ribosomal subunits. Active against many aerobic gram-negative organisms and some aerobic gram-positive bacteria.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
